LivaNova (LIVN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Briana Gotlin - VP-IRVladimir Makatsaria - CEOAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - Chief Financial OfficerRick Wise - Managing Director - Medical Technology & SuppliesDavid Roman - Managing DirectorStephanie Bolton - President of Global Epilepsy Conference Call Participants Adam Maeder - Senior Research AnalystMichael Sarcone - AnalystMike Matson - Senior Equity Research AnalystDavid Rescott - Senior Rese ...

Core Insights - ReShape Lifesciences is presenting pre-clinical data on its proprietary Diabetes Neuromodulation device at the 12th Annual Minnesota Neuromodulation Symposium, showcasing a novel approach to treating diabetes and hypoglycemia without cardiac side effects [1][4] Group 1: Technology and Mechanism - The Diabetes Neuromodulation technology employs Hypoglycemia Vagus Nerve Stimulation (HVNS) to stimulate the sub-diaphragmatic posterior vagus nerve, effectively increasing blood glucose levels during hypoglycemic episodes [3] - HVNS demonstrated the ability to raise blood glucose levels from a baseline of 45 mg/dL to 58 mg/dL and from 51 mg/dL to 68 mg/dL in a Type 1 diabetic swine model after 30 minutes of stimulation [3] - The technology avoids impacting heart rate, blood pressure, or respiration, addressing limitations of conventional vagal stimulation techniques [3][7] Group 2: Clinical Data and Efficacy - Pre-clinical results showed that HVNS increased glucagon levels from 4.1 pmol/L to 12.3 pmol/L and from 3.5 pmol/L to 7.6 pmol/L, indicating a significant physiological response [3] - The mean heart rate remained stable during stimulation, with vomiting only observed at higher amplitudes, suggesting a clear therapeutic window for effective treatment [3] Group 3: Future Development and Market Potential - The company plans to seek non-dilutive funding and collaborate with leading researchers and corporate partners to advance the commercialization of the Diabetes Neuromodulation device [4] - The ReShape Diabetes Neuromodulation system is positioned as a minimally invasive alternative to traditional diabetes management methods, potentially improving the quality of life for individuals with Type 1 or Type 2 diabetes [5][8]

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Ament of Cherry Creek Neurology presented his study entitled, "Adjunctive N ...

New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, t ...

Core Viewpoint - NeurAxis, Inc. is set to present at the Planet MicroCap Showcase: VEGAS 2025, highlighting its focus on neuromodulation therapies for chronic conditions in both children and adults [1][2]. Company Overview - NeurAxis, Inc. specializes in medical technology aimed at neuromodulation therapies to treat chronic and debilitating conditions [3]. - The company is advancing its proprietary IB-Stim™ therapy, which utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, and is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 [3]. - Ongoing clinical trials are being conducted for PENFS in various pediatric and adult conditions with significant unmet healthcare needs [3]. Event Details - The presentation will take place on April 23, 2025, at 11:00 AM EST during the Planet MicroCap Showcase: VEGAS 2025 [1][2]. - Investors interested in one-on-one meetings with NeurAxis can register for the event, which will be held at the Paris Hotel & Casino in Las Vegas, NV [2].

Core Viewpoint - CVRx, Inc. anticipates first quarter 2025 revenue of approximately $12.3 million, reflecting a growth of about 15% compared to the same period in 2024, despite falling short of expectations due to seasonal factors and the integration of new sales representatives [1][2][3]. Financial Performance - Expected total revenue for Q1 2025 is approximately $12.3 million, up from $10.8 million in Q1 2024, indicating a 15% increase [3]. - Q1 2024 revenue breakdown includes approximately $11.2 million from the U.S. and $1.1 million from Europe [3]. Sales and Market Strategy - The company is focused on enhancing Barostim adoption through a strengthened sales organization, having recruited new high-quality sales representatives [2]. - The first quarter of 2025 experienced seasonal softness, affecting revenue as patients scheduled procedures around insurance coverage and deductibles [2]. Operational Metrics - As of March 31, 2025, CVRx had 227 active implanting centers in the U.S., an increase from 223 as of December 31, 2024 [4]. - The number of sales territories in the U.S. decreased by 3 to a total of 45 during the first quarter of 2025 [4]. Cash Position - As of March 31, 2025, the company reported cash and cash equivalents of $102.7 million [4]. - During the first quarter, CVRx issued 543,462 shares of common stock for gross proceeds of $9.5 million under its at-the-market offering [4]. Upcoming Events - The company plans to release its full financial and operating results for Q1 2025 after market close on May 8, 2025, followed by a conference call at 4:30 p.m. Eastern Time [5][6].